FreeFree RFPs on Craxy AI — no subscription required

Ready to bid on this RFP?

Sign up free to generate a complete proposal draft instantly — Craxy AI reads the RFP, drafts every section, and matches your past work.

Request for Proposals (RFP) - BARDA Vaccine Medical Countermeasures for Pandemic Influenza Preparedness & Response

Federal · Department of Health and Human ServicesDue Friday, October 30, 2026
Client
Department of Health and Human Services
RFP Number
MEDI-8015
Posted
—
Category
Medical Services
Budget
Looking for Proposals
NAICS
541714
Set-aside
No Set aside used
Contact
Laura Saddison

Description

AI Generated

The buyer requires a vendor to provide a vaccine medical countermeasures service in Washington, DC. Under this five-year contract, the selected vendor must supply medical countermeasures, including vaccines, antigens, and adjuvants, for pandemic preparedness and response or as required during a public health emergency. The vendor must produce antigens and vaccines against the influenza virus or other viruses with pandemic potential. Additionally, the vendor must produce antigens, vaccines, and adjuvants to support efforts to further improve influenza vaccines. Only United States organizations are eligible to participate in this opportunity. The vendor may perform the requested work either onsite or offsite. The buyer is currently seeking proposals and accepts digital submissions via email or online. Interested bidders must submit all questions regarding this opportunity no later than August 31, 2026.

Key solicitation details

AI-extracted from 19_75A50126R0001_RFP Att 19 Surge Manufacturing and Supply Chain Readiness Assessment.pdf, 18-75A50126R00001_RFP Att 18 BCP SCP Continuity Plans.pdf, 17-75A50126R00001_RFP Att 17 Manufacturing Plan.pdf. Confirm against the original documents before bidding.

The buyer is procuring vaccine medical countermeasures (MCMs), including vaccines, antigens, and adjuvants, for pandemic preparedness, response, and influenza vaccine improvements. The contract duration is five years, and eligible bidders are onshore USA organizations only.

Issued by
BARDA
Questions due
August 31, 2026
How to submit
Digital via Email or Online
Contract term
five years
Place of performance
Onsite or offsite, Washington, DC

Scope of work

  • Provide vaccine medical countermeasures, antigens, and adjuvants for public health emergencies
  • Produce antigens and vaccines against influenza or other viruses with pandemic potential
  • Produce antigens, vaccines, and adjuvants to improve influenza vaccines
  • Submit Surge Manufacturing and Supply Chain Readiness Assessments upon COR direction
  • Develop, maintain, and submit a comprehensive Business Continuity Plan (BCP)
  • Develop, maintain, and submit a Supply Continuity Plan (SCP)
  • Develop, maintain, and submit a comprehensive Manufacturing Plan
  • Submit a Bill of Materials (BOM) as an attachment to the Manufacturing Plan

Minimum qualifications

  • USA Organization Only (Onshore)

Documents to include with the bid

  • Surge Manufacturing and Supply Chain Readiness Assessment
  • Business Continuity Plan (BCP)
  • Supply Continuity Plan (SCP)
  • Manufacturing Plan
  • Bill of Materials (BOM)

Official SAM.gov notice

Solicitation number
75A50126R00001_RFP_NPIVS_27
Agency
Department of Health and Human Services
Buying office
Office of Assistant Secretary for Preparedness and Response › Barda - Aspr / Daappo / Barda Dcma
Notice type
Solicitation
Responses due
Oct 30, 2026, 5:00 PM ET
Posted on SAM.gov
Aug 17, 2026
NAICS
541714 · Research and Development in Biotechnology (except Nanobiotechnology)
Product/service code
AN12
Set-aside
No Set aside used
Place of performance
Washington, DC, 20024
Contracting contact
Laura Saddison
Laura.Saddison@hhs.gov
Read the official notice description

BARDA seeks Contractor(s) to support the continuation of the Vaccine Medical Counermeasures (MCM's) for Pandemic Influenza Preparedness and Response Program. Contractors will furnish all the necessary services, qualified personnel, materials, supplies, equipment and facilities (U.S. facilities preferred) not otherwise provided by the USG as needed to provide MCMs, such as vaccines, antigens, and adjuvants, for pandemic preparedness and response or as required in response to a public health emergency; produce antigen and vaccines against influenza virus or other viruses with pandemic potential as required by BARDA; produce antigens, adjuvants, and/or vaccines to support USG efforts to further improve influenza vaccines (for which feasibility data is available); and support rapid regulatory decisions and manufacturing readiness by generating and submitting to FDA all relevant data (e.g., analytical, nonclinical, clinical, and/or chemistry, manufacturing, and controls (CMC)), including data generated during interpandemic periods. Mandatory Qualification Requirements: To be eligible for award, the Offeror must produce vaccines against influenza and influenza strains with pandemic potential; must demonstrate a successful experience in the manufacturing of influenza vaccine by: 1. Holding a U.S. influenza vaccine license; or 2. Have developed an influenza vaccine as evidenced by: a. Submission of a Biologics License Application (BLA) for seasonal or pandemic influenza vaccine Please see full solicitation details and proposal submission instructions detailed in attachments 01-19 of this notice.

Source: SAM.gov contract opportunities data (U.S. federal public data).

Incumbent

Likely prior awards for this requirement

Likely match

Awarded by the same buying office (75A501) with descriptions matching "vaccine", performed in DC. The notice does not name its current contract, so confirm before relying on it.

Vendor and awardValueEnds
ADVANCED TECHNOLOGY INTERNATIONAL75A50124F61008 · OT TASK ORDER 8-RAPID PANDEMIC INFLUENZA AND EMERGING INFECTIOUS DISEASE VACCINE DEVELOPME$418.7MSep 16, 2035

Market context

Awards in the same category (Research and Development in Biotechnology (except Nanobiotechnology)). This is not this requirement's award history.

Recent similar awards: Department of Health and Human Services, NAICS 541714, performed in DC

Vendor and awardValueEnds
ALBERT B. SABIN VACCINE INSTITUTE, INC. (THE)75A50123C00010 · THE SCOPE OF THE PROPOSED PROGRAM INCLUDES MANUFACTURE OF SABIN?S SUDAN EBOLAVIRUS VACCINE$163.1MSep 30, 2030
MELINTA THERAPEUTICS, LLC75A50123C00022 · ADVANCE THE DEVELOPMENT OF TWO ANTIBIOTICS FOR USE IN THE PEDIATRIC POPULATION FOR THE TRE$47.5MJun 30, 2030
ALBERT B. SABIN VACCINE INSTITUTE, INC. (THE)75A50119C00055 · THIS CONTRACT IS TO ADVANCE THE DEVELOPMENT OF MONOVALENT VACCINES FOR PREVENTION OF MARBU$145.4MSep 30, 2027
BATTELLE MEMORIAL INSTITUTE75A50125F61004 · USE OF A HUMAN-RELEVANT SMALL ANIMAL MODEL OF SULFUR MUSTARD (SM)-INDUCED INHALATION INJUR$7.6MMar 28, 2027
INFLO MEDICAL INC75A50124C00019 · THE OVERALL OBJECTIVE OF THIS CONTRACT IS TO IMPROVE THE SAFETY METRICS FOR EXTRACORPOREAL$747.4KJun 21, 2026

Top vendors in this category: Department of Health and Human Services, NAICS 541714, since Oct 1, 2023

1,469 contract awards in this NAICS over the period.

  1. 1. ADVANCED TECHNOLOGY INTERNATIONAL$1.6B
  2. 2. ALBERT B. SABIN VACCINE INSTITUTE, INC. (THE)$356.9M
  3. 3. AMGEN USA INC$345.8M
  4. 4. START2 GROUP, INC.$223.1M
  5. 5. PPD DEVELOPMENT LP$197.2M

Source: USAspending.gov federal award data (U.S. federal public data). A contract is called the incumbent only when the notice or its documents cite it by number.

Verify important details

Document check

Confirm submission instructions and amendments with the issuing agency before responding.

19 available filesDocuments checked

Personalized fit score

Sign up free to see how well this opportunity fits your company — based on your saved profile.

Sign up to see your fit score